Bayram Doğan, Sekmek Serhat, Kayaalp Mehmet, Bardakçı Murat, Hafızoğlu Emre, Uçar Gökhan, Algin Efnan, Bal Oznur, Civelek Burak, Şendur Mehmet Ali Nahit, Kos Fahriye Tugba, Uncu Dogan
Department of Medical Oncology, Ankara City Hospital, Ankara, 06000 Turkey.
Department of Medical Oncology, Ankara University, Ankara, Turkey.
Indian J Thorac Cardiovasc Surg. 2024 Nov;40(6):660-668. doi: 10.1007/s12055-024-01741-6. Epub 2024 May 14.
Thymic epithelial tumors represent the most common cause of anterior mediastinal masses in adults. Among these tumors, thymomas constitute the majority, whereas thymic carcinomas are less prevalent and associated with a poorer prognosis. This study seeks to investigate the clinical and prognostic factors of these rare entities, thymoma, and thymic carcinomas.
We conducted a retrospective analysis on a cohort of 60 patients diagnosed with thymoma and thymic carcinoma, who were under follow-up at our clinic between January 1998 and February 2023. The clinical characteristics and prognostic factors of these patients were analyzed separately.
Thymomas accounted for 75% of the cases. The median age at diagnosis was 46 years in both patient groups. Masaoka stage 4 was observed in 28.9% of thymoma patients and 66.7% of thymic carcinoma patients. The median overall survival (mOS) for thymoma patients was 261.4 months, while it was 9.23 months for patients with thymic carcinoma. Curative surgery emerged as a prognostic factor significantly influencing overall survival in both thymoma and thymic carcinoma patients.
Our study highlights the significance of Eastern Cooperative Oncology Group (ECOG) performance status and curative surgery as prognostic factors affecting overall survival in thymoma patients. In thymic carcinoma, only curative surgery was found as a prognostic factor. These findings may enhance patient care and guide personalized treatment strategies. Further investigations and prospective studies are warranted to corroborate and expand upon these results.
胸腺上皮肿瘤是成人前纵隔肿块最常见的病因。在这些肿瘤中，胸腺瘤占大多数，而胸腺癌则较少见且预后较差。本研究旨在调查这些罕见实体（胸腺瘤和胸腺癌）的临床及预后因素。
我们对1998年1月至2023年2月在我院接受随访的60例诊断为胸腺瘤和胸腺癌的患者进行了回顾性分析。分别分析了这些患者的临床特征和预后因素。
胸腺瘤占病例的75%。两组患者的诊断时中位年龄均为46岁。28.9%的胸腺瘤患者和66.7%的胸腺癌患者观察到Masaoka 4期。胸腺瘤患者的中位总生存期（mOS）为261.4个月，而胸腺癌患者为9.23个月。根治性手术是影响胸腺瘤和胸腺癌患者总生存期的一个显著预后因素。
我们的研究强调了东部肿瘤协作组（ECOG）体能状态和根治性手术作为影响胸腺瘤患者总生存期的预后因素的重要性。在胸腺癌中，仅发现根治性手术是一个预后因素。这些发现可能会改善患者护理并指导个性化治疗策略。有必要进行进一步的研究和前瞻性研究以证实并扩展这些结果。
